TIAA CREF Investment Management LLC reduced its position in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) by 3.2% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 251,861 shares of the company’s stock after selling 8,429 shares during the quarter. TIAA CREF Investment Management LLC owned about 0.26% of Bio-Path Holdings worth $208,000 at the end of the most recent quarter.
Separately, Bank of New York Mellon Corp increased its holdings in Bio-Path Holdings by 1.7% during the 1st quarter. Bank of New York Mellon Corp now owns 311,645 shares of the company’s stock worth $257,000 after purchasing an additional 5,172 shares in the last quarter. 15.16% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “TIAA CREF Investment Management LLC Has $208,000 Position in Bio-Path Holdings, Inc. (BPTH)” was originally reported by BBNS and is the property of of BBNS. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://baseballnewssource.com/markets/bio-path-holdings-inc-bpth-position-decreased-by-tiaa-cref-investment-management-llc/1566162.html.
Several equities analysts have recently issued reports on the company. HC Wainwright set a $5.00 target price on Bio-Path Holdings and gave the company a “buy” rating in a report on Friday, August 11th. Zacks Investment Research lowered Bio-Path Holdings from a “buy” rating to a “hold” rating in a report on Wednesday, July 12th. Finally, ValuEngine lowered Bio-Path Holdings from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st.
Shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) traded up 7.89% during trading on Friday, reaching $0.41. The company’s stock had a trading volume of 1,037,732 shares. The company’s market capitalization is $41.02 million. The firm’s 50-day moving average price is $0.31 and its 200-day moving average price is $0.50. Bio-Path Holdings, Inc. has a one year low of $0.25 and a one year high of $1.54.
Bio-Path Holdings (NASDAQ:BPTH) last released its quarterly earnings data on Thursday, August 10th. The company reported ($0.03) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.02) by ($0.01). On average, equities analysts anticipate that Bio-Path Holdings, Inc. will post ($0.08) earnings per share for the current year.
Bio-Path Holdings Company Profile
Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.
Receive News & Ratings for Bio-Path Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path Holdings Inc. and related companies with our FREE daily email newsletter.